Granulocyte colony-stimulating factor therapy reduces hospitalizations and improves chemotherapy administration in elderly breast cancer patients, but increases overall Medicare costs during first year of therapy.
Suja S. Rajan, MHA, MS, PhD
Advertisement
Articles by Suja S. Rajan, MHA, MS, PhD
Advertisement
Latest Updated Articles
- Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy
Published: February 13th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
4
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
5
